Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

In a report released yesterday, David Toung from Argus Research maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The company’s shares opened today at $129.75.

FPLC column is a single use product suitable for FPLC and ÄKTA design™ chromatography systems. It is recommended to work with approximately 8 ml of packed bead bed volume. The package contains ...

Abbott (NYSE: ABT) recently reported its Q4 results, with revenues marginally below and earnings meeting the street expectations. The company reported revenue of $10.97 billion and earnings of $1. ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

2025 Adjusted Tax Rate Forecast: 16% to 17%. Abbott Laboratories (NYSE:ABT) achieved a 9.5% sales growth excluding COVID testing, demonstrating strong performance across its business segments.

Good morning and thank you for standing by. Welcome to Abbott’s Fourth Quarter 2024 Earnings Conference Call. All participants will be able to listen only until the question-and-answer portion ...

In a report released on January 17, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price target of $135.00. The company’s ...